国产九价HPV疫苗相关专利获中国专利金奖

Core Points - The 14th China International Patent Technology and Product Trade Fair and the 25th China Patent Award Ceremony were held in Dalian, Liaoning [1] - The patent technology "Shortened Human Papillomavirus Type 16 L1 Protein" developed by Xiamen Wantai Biological Pharmacy and Xiamen University won the China Patent Gold Award [1] Technology Features - The technology utilizes E. coli as an expression vector, creating a domestic production route for HPV vaccine antigens, differing from international methods [3] - The domestically developed bivalent HPV vaccine "Xinkening" shows comparable immune effects to imported vaccines in multiple studies [3] - Compared to the eukaryotic expression systems commonly used abroad, this technology simplifies the process, increases yield, and reduces costs [3] Application and Market Entry - The first domestic bivalent HPV vaccine using this patented technology was launched in 2019, covering over 360 cities nationwide and included in free vaccination programs in 15 provincial governments [3] - In 2021, the vaccine received prequalification from the World Health Organization and gained market access in 21 countries, including Thailand, Morocco, and Indonesia [3] - The first domestic nine-valent HPV vaccine is set to launch in September 2025, with research published in The Lancet Infectious Diseases indicating comparable protective efficacy to imported counterparts [3] - The vaccine is priced at 499 yuan per dose and is currently being administered in several provinces, targeting women aged 9 to 45 [3]